Genfit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Genfit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Genfit Today - Breaking & Trending Today

Genfit (EPA:GNFT) Trading Down 0.8%

Shares of Genfit S.A. (EPA:GNFT – Get Free Report) fell 0.8% on Thursday . The company traded as low as €3.19 ($3.39) and last traded at €3.21 ($3.41). 36,724 shares were traded during mid-day trading, The stock had previously closed at €3.24 ($3.44). Genfit Price Performance The business’s fifty day moving average is €3.26 and […] ....

Genfit Company Profile , Get Free Report , Urea Cycle Disorder , Organic Acidemia Disorder , Blood Ammonia , Genfit Daily , Epa Gnft ,

Neurocrine Biosciences (NASDAQ:NBIX) & Genfit (NASDAQ:GNFT) Head-To-Head Review

Genfit (NASDAQ:GNFT – Get Free Report) and Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, valuation, earnings, profitability, institutional ownership, risk and dividends. Institutional & Insider Ownership 8.8% of Genfit shares are […] ....

United States , San Diego , Neurocrine Biosciences , Genoscience Pharma , Neurocrine Bioscience , Neurocrine Biosciences Inc , Abbvie Inc , Xenon Pharmaceuticals Inc , Voyager Therapeutics Inc , Heptares Therapeutics , Mitsubishi Tanabe Pharma Corporation , Idorsia Pharmaceuticals Ltd , Takeda Pharmaceutical Company , Get Free Report , Given Genfit , Urea Cycle Disorder , Organic Acidemia Disorder , Heptares Therapeutics Limited , Takeda Pharmaceutical Company Limited , Voyager Therapeutics , Genfit Daily , Nasdaq Gnft , Stock Comparison , Stock Analysis ,

Head to Head Contrast: Genfit (NASDAQ:GNFT) vs. Neurocrine Biosciences (NASDAQ:NBIX)

Genfit (NASDAQ:GNFT – Get Free Report) and Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk. Volatility and Risk Genfit has a beta of 1.08, […] ....

United States , San Diego , Genoscience Pharma , Neurocrine Biosciences , Neurocrine Bioscience , Voyager Therapeutics Inc , Abbvie Inc , Xenon Pharmaceuticals Inc , Heptares Therapeutics , Mitsubishi Tanabe Pharma Corporation , Takeda Pharmaceutical Company , Idorsia Pharmaceuticals Ltd , Neurocrine Biosciences Inc , Get Free Report , Given Genfit , Urea Cycle Disorder , Organic Acidemia Disorder , Heptares Therapeutics Limited , Takeda Pharmaceutical Company Limited , Voyager Therapeutics , Genfit Daily , Nasdaq Gnft , Stock Comparison , Stock Analysis ,

Genfit (OTCMKTS:GNFTF) vs. VBI Vaccines (NASDAQ:VBIV) Financial Review

Genfit (OTCMKTS:GNFTF – Get Free Report) and VBI Vaccines (NASDAQ:VBIV – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Earnings & Valuation This table compares Genfit and VBI […] ....

United Kingdom , United States , Genoscience Pharma , Brii Biosciences , Vaccines Inc , National Research Council Of Canada , Scivac Therapeutics Inc , Coalition For Epidemic Preparedness Innovations , Get Free Report , Urea Cycle Disorder , Organic Acidemia Disorder , Brii Biosciences Limited , National Research Council , Middle East , Epidemic Preparedness Innovations , Scivac Therapeutics , Genfit Daily , Otcmkts Gnftf , Stock Comparison , Stock Analysis ,

Leerink Partnrs Comments on Genfit S.A.'s FY2026 Earnings (NASDAQ:GNFT)

Genfit S.A. (NASDAQ:GNFT – Free Report) – Research analysts at Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for Genfit in a report issued on Monday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings per share of ($0.67) for the year. The consensus estimate for Genfit’s current […] ....

Leerink Partnrs , Shaughnessy Asset Management , Citadel Advisors , Envestnet Asset Management Inc , Optiver Holding , Genfit Company Profile , Free Report , Asset Management , Get Free Report , Urea Cycle Disorder , Organic Acidemia Disorder , Genfit Daily , Nasdaq Gnft , Earnings Estimates ,